One pill a day? new trial aims to simplify life-saving meds after liver transplant
NCT ID NCT06354179
First seen Nov 25, 2025 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This study tests whether giving immunosuppressive drugs just once a day, instead of twice, helps liver transplant patients stick to their medication and feel better. About 162 adults who recently received a liver transplant will be randomly assigned to different dosing schedules. The goal is to see if once-daily dosing is as safe and effective as the standard twice-daily regimen, while also improving adherence and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
APHP
RECRUITINGMarseille, 13000, France
Contact Email: •••••@•••••
Contact
-
Beaujon hospital - APHP
RECRUITINGClichy, 92110, France
Contact Email: •••••@•••••
Contact
-
Bordeaux university hospital
RECRUITINGPessac, 33604, France
Contact Email: •••••@•••••
Contact
-
CHU de Besançon - Hôpital Jean Minjoz
RECRUITINGBesançon, 25000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Dijon Bourgogne
RECRUITINGDijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHu de Grenoble
NOT_YET_RECRUITINGGrenoble, 38043, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Lille university hospital
RECRUITINGLille, 59000, France
Contact Email: •••••@•••••
Contact
-
Limoges university hospital
RECRUITINGLimoges, 87042, France
Contact Email: •••••@•••••
Contact
-
Lyon university hospital
RECRUITINGLyon, 69000, France
Contact Email: •••••@•••••
Contact
-
Montpellier university hospital
RECRUITINGMontpellier, 34000, France
Contact Email: •••••@•••••
Contact
-
Nice university hospital
RECRUITINGNice, 06202, France
Contact Email: •••••@•••••
Contact
-
Paul Brousse Hospital - APHP
RECRUITINGVillejuif, 94800, France
Contact Email: •••••@•••••
Contact
-
Pitie Salpetriere hospital - APHP
RECRUITINGParis, 75013, France
Contact Email: •••••@•••••
Contact
-
Poitiers university hospital
RECRUITINGPoitiers, 86000, France
Contact Email: •••••@•••••
Contact
-
Rennes university hospital
RECRUITINGRennes, 35033, France
Contact Email: •••••@•••••
Contact
-
Strasbourg university hospital
RECRUITINGStrasbourg, 67000, France
Contact Email: •••••@•••••
Contact
-
Toulouse university hospital
RECRUITINGToulouse, 31000, France
Contact Email: •••••@•••••
Contact
-
Tours university Hospital
RECRUITINGTours, 37000, France
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus and mycophenolate mofetil (immunosuppressants)
What this could lead to
If successful, this could simplify lifelong medication schedules for liver transplant patients, making it easier to stick to treatment and potentially improving quality of life.
What could go wrong
This is a Phase 4 study with 162 participants, so results may not apply to all patients. Simplifying dosing might not improve adherence or could slightly increase rejection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.